BioSyent Inc. (CVE:RX)’s earnings report is awaited on March, 20., as reported by RTT. Analysts have anticipation on stock’s EPS of $0.11. That’s up 10.00 % from last year?s $0.1 EPS. If the current EPS of $0.11 is accurate, V_RX’s profit could hit $1.58 million. Wall Street now predicts 22.22 % EPS growth despite BioSyent Inc. previous quarter’s EPS of $0.09. The stock increased 0.97% or $0.08 during the last trading session, touching $8.3.Currently BioSyent Inc. is after 0.00% change in last March 14, 2018. RX has 200 shares volume. RX underperformed the S&P 500 by 4.37%.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally.The firm is valued at $119.38 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer.The P/E ratio is 21.96. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

There’s an important BioSyent Inc. (CVE:RX) news posted by Midasletter.com. It’s an item titled: “Aurora Cannabis Inc (TSE:ACB) CCO Cam Battley on Spin-out and Canopy Growth Corp – Constellation Brands Tie-up – Midas Letter” on August 18, 2018.